Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BK1803 route of administration comparison in healthy infants
jRCT2031260414Not yet recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of BK1803 in pertussis, diphtheria, Tetanus and 3 more (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Seroprotection rates at Visit 4. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BK1803
03
Conditions
pertussisdiphtheriaTetanuspoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on jRCT2031260414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260414.